Fed. Circ. Reaffirms Written Description Doctrine
In a long-awaited decision in Ariad Pharmaceuticals Inc.'s patent infringement suit against Eli Lilly & Co., a federal appeals court majority reaffirmed Monday that there is a written description requirement for...To view the full article, register now.
Already a subscriber? Click here to view full article